Analysts have been eager to weigh in on the Healthcare sector with new ratings on Annovis Bio (ANVS – Research Report), Gilead Sciences (GILD ...

Analyst Salveen Richter of Goldman Sachs maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price target of $73.00. Salveen Richter has given his Hold rating due to a ...

The biopharmaceutical giant topped its earnings and revenue estimates thanks to strong sales of its HIV, liver disease, and ...

The drug benefited people whose tumors have “ultralow” levels of HER2 protein, a result that could extend its reach in HER2-positive breast cancer.

Pharma’s pandemic-era halo is slipping. After tracking a surge in the industry’s reputation, PatientView found patient groups ...

Since Gilead Sciences introduced a groundbreaking hepatitis C treatment a decade ago, the global landscape in combating the ...

Despite hot inflation data, earnings reinforced the promise of artificial intelligence. This week is packed with earnings, ...

Gilead Sciences Inc. is aiming to capitalize on the early August 2022 buyout of privately held U.K. biotech Mirobio Ltd. with ...

Integrating AI into electronic messaging systems may help relieve physician burden and improve patient education but still ...

Maintaining their stance, an analyst from Oppenheimer continues to hold a Outperform rating for Gilead Sciences, targeting a price of $105. Maintaining their stance, an analyst from Morgan Stanley ...

After a negative phase 3 readout, Gilead Sciences is taking a $2.4 billion impairment charge on Trodelvy, which serves as the ...

Revenues for the firm's antibody-drug conjugate Trodelvy grew 39 percent year over year in Q1 2024 due to increased demand.